Skip to main content
ANAB logo

ANAB · Anaptysbio, Inc

Track ANAB — free
$46.63 -0.77 (-1.62%) At close · Nov 20
Market Cap
$1.39B
Shares
29.90M
Volume · Nov 20 432.48K Avg daily vol (3M) 494.29K

Price & Indicators

 

Key stats

Close
$46.63
Fri 20 Nov
Open
$47.49
Fri 20 Nov
Average volume, 30 days
430K
shares a session
Short interest
5.1M
16.9% of shares · 10.8 days to cover
Day range
$46.05$47.71
Open $47.49 Close $46.63
Closing range since split
$45.43$69.81
Close $46.63 33.2% under the high
Short volume, last session
54%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 12
Price history
Jan 2020 to Nov 2026

The closing range begins at the captured split on Apr 20, 2026.

Up next

May 11, 2027 Est · unconfirmed · in 24 wks

Latest documents

2026
Nov 17
Investor event
Jemperly wins rectal cancer approval; GSK court ruling pending

Anaptis Bio, now a virtual royalty company after its April 20th separation, expects Jemperly royalties to grow with the rectal cancer approval. The CEO's best guess for a Delaware court decision in its GSK litigation is December or January.

5 source passages
We successfully completed that transaction on April 20th of this year, so six, seven months ago. We've transformed the company into a virtual organization. And then very recently, not in the Q3 numbers, we had an approval in DMMR rectal cancer, first immunotherapy approved in rectal cancer to date. It's in front of the chancellor in Delaware Chancery Court. Our best way to think about guidance is somewhere in, given what the chancellor said, is I need at least multiple months, sometime in December or January is our best guess. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2027 Q1, ended Sep 30
Jemperli wins accelerated rectal cancer approval amid revenue decline

AnaptysBio reported $30.3 million in collaboration revenue for the three months ended September 30, 2026, down from $76.3 million, while Jemperli received accelerated FDA approval for previously untreated stage II and III dMMR/MSI-H locally advanced rectal cancer.

Revenue $30.27M ▼ 60.3% Net income $3.88M ▼ 74.4% Diluted EPS $0.11 ▼ 78.8%
Read from the MD&A section
2 source passages
Collaboration revenue was $30.3 million for the three months ended September 30, 2026, compared to $76.3 million for the three months ended September 30, 2025. In October 2026, the FDA granted accelerated approval for Jemperli in patients with previously untreated stage II and III mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer. Open the document at this passage
Nov 12
Current report 8-K
Jemperli reaches $1.0 billion in global net sales

AnaptysBio reported Jemperli global net sales of $1.0 billion (£753 million) through September 30, 2026, up 29% year-over-year, and U.S. approval in stage II and III MSI-H/dMMR locally advanced rectal cancer. A GSK and Tesaro judgment is anticipated in calendar Q4 2026 or Q1 2027.

Financial results
4 source passages
SAN DIEGO, November 12, 2026 — AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the fiscal first quarter ended September 30, 2026, and provided a business update. $1.0 billion (£753 million) in global net sales for the nine months ended September 30, 2026, representing 29% year-over-year growth1 Jemperli approved in the U.S. as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/ mismatch repair deficient (dMMR) locally advanced rectal cancer Anaptys is seeking reversion of Jemperli rights as a remedy; the Company anticipates a judgment in calendar Q4 2026 or Q1 2027 Open the document at this passage
Sep 21
Current report 8-K
Current report

AnaptysBio, Inc. reported Jemperli sales of $644 million (£480 million) for the six months ended June 30, 2026, up 34% year-over-year; collaboration revenue was $53.0 million and net income from continuing operations was $176.4 million.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$232.39M
Trailing 12 months
Net income (TTM)
−$26.79M
Trailing 12 months
Revenue growth YoY
-60.3%
Year over year
Operating margin
17.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$135.39M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+20.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
16.9%
Latest settlement · 10.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Weak Sentiment Very Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 35.9 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −10%
below
Price vs 50-day avg −5%
below
RSI (14) 46
neutral
MACD trend Positive
52-week position 5%
near low
Momentum
relative strength
Weak
1-month return −4%
trailing
6-month return −9%
trailing
YTD return +44%
this year
Relative strength 0%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $49 › 200d $52 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +48 funds added
Insider flow Accumulating
Net +$17.2M over 90 days · 0% sells
Short interest Falling
16.89% of shares out · ▼ -6.3% MoM · 10.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
229 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Excellent
Revenue growth +157%
Y/Y
EPS growth +91%
Y/Y
Free cash flow $19.6M
Buyback $100.0M
remaining
Quant / Vol
risk profile
Very High
Volatility 61%
annualized · 1-yr
Max drawdown −35%
past year
ATR 4.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 12, 2026
as early as 2029
Annualized Jemperli royalties payable to Anaptys at least $390M
calendar H2 2027
Paydown $270M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
2 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−10% Bearish
Price vs 50-day avg
−5% Neutral
RSI (14)
46 Neutral
MACD trend
Positive Bullish
52-week position
5% Bearish
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $49 › 200d $52 — 200d above 50d
Institutional flow Accumulating
+6% holders QoQ · +48 funds added
Insider flow Accumulating
Net +$17.2M over 90 days · 0% sells
Short interest Falling
16.89% of shares out · ▼ -6.3% MoM · 10.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
229 holders — near 3-yr high, broad support
Price context
position in its range since split · 2026-04-20
Range low $45 Now $47 · 5% Range high $70
vs 200-day avg -10% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Non-cash interest expense $19M the three months ended September 30, 2026 filing —
Royalties and sales milestones accrued $330M through September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ANAB
Anaptysbio, Inc
this stock
$1.39B — +157.0% — 16.9%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$62.17B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
229
% held
103.1%
Net QoQ
+689.5K sh
Top holder
EcoR1 Capital, LLC
Held Float
View
Held by Funds
Fund positions
223
View
Short & Settlement
Short Interest Falling
Shares short
5.1M
Days to cover
10.8d
Change
-341.9K sh
View
Short Volume
Short vol %
54%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
6.7K
Value
$327.0K
As of
Oct 5, 2026
View
Off-Exchange
Off-exchange %
41.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$17.2M
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$234.6M
Net income (FY)
$-13.2M
EPS diluted
$-0.31
View
Buybacks
Authorized
$100.0M
Remaining
$100.0M
Spent Remaining
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
23

Anaptis Bio, now a virtual royalty company after its April 20th separation, expects Jemperly royalties to grow with the rectal cancer approval. The CEO's best guess for a Delaware court decision in its GSK litigation is December or January.

View
Proposed Sales
Value
$249.4K
Shares
5.0K
Filed
Oct 1, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Anaptys Reports Fiscal First Quar…
Published
Nov 12, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
ANAB +0.8% -4.3% -9.0% -3.4% +44.3%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +9.4% +4.9% +0.2% +5.3% +43.1%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$100.00M
Spent (derived)
$0
Remaining
$100.00M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1370053 CUSIP 032724106 13F (30d) 231 filings 212 filers Visit website Investor relations